SETD2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL3602478	0.50	15/20
SCHEMBL3602482	0.50	15/20
SCHEMBL3607939	0.52	12/20
SCHEMBL3607941	0.52	12/20
SCHEMBL5994036	0.43	4/20
SCHEMBL6648367	0.42	4/20
SCHEMBL7057346	0.41	4/20
SCHEMBL7057347	0.41	4/20
SCHEMBL112912	0.39	4/20
SCHEMBL7057055	0.39	4/20
SCHEMBL7057059	0.39	4/20
SCHEMBL7054358	0.39	4/20
SCHEMBL7054360	0.39	4/20
SCHEMBL2130180	0.37	4/20
SCHEMBL2287080	0.69	3/20
SCHEMBL2287090	0.69	3/20
SCHEMBL2287096	0.69	3/20
SCHEMBL2284758	0.68	3/20
SCHEMBL2284764	0.68	3/20
SCHEMBL2284776	0.68	3/20

Clinical trials — most relevant to SETD2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas	PHASE1/PHASE2	UNKNOWN
Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL	PHASE1/PHASE2	COMPLETED
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis	PHASE1/PHASE2	RECRUITING
Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2	PHASE2	ACTIVE_NOT_RECRUITING
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)	PHASE2	ACTIVE_NOT_RECRUITING
Valproic Acid and Platinum-based Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma	PHASE2	COMPLETED
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes	PHASE1/PHASE2	COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL)	PHASE1	COMPLETED
FdCyd and THU for Advanced Solid Tumors	PHASE1	COMPLETED
Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction	PHASE1	WITHDRAWN
Evaluating Safety & Efficacy Belinostat Combo w Nivo Alone & w Ipi in Patients w Treated Metastatic/Advanced Carcinomas w ARID1A Lof Mutation	PHASE1	WITHDRAWN
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load	PHASE1	COMPLETED
The Efficacy of Allo-HSCT in ND HR-CBF-AML	nan	RECRUITING
An Expanded Access Program to Axitinib is Available for Patients With Advanced Forms of Kidney Cancer (Ductal; Papillary; Chromophobic; Oncocytic) With Mutations in VHL, PBRM1 / BAP1, SETD2, VEGF)	nan	NO_LONGER_AVAILABLE
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
Long Non-coding RNAs and Their Role on Epigenome as Diagnostic Markers in Childhood Acute Lymphoblastic Leukemia of T Cells.	nan	UNKNOWN
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma	nan	UNKNOWN
Mechanisms of Immune Deficiency	nan	UNKNOWN
Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two Therapies	nan	WITHDRAWN
Clinical, Radiological, Histologic and Molecular Features of a Cohort of Melanocytic Tumors of the Central Nervous System	nan	UNKNOWN
Target of Suv420h1/2 in Hepatocytes	nan	RECRUITING
The Molecular Pathogenesis Study of Cataract	nan	UNKNOWN
Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia	nan	COMPLETED
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients	nan	RECRUITING
Epigenomic Profiling of Circulating Cell-Free DNA (cfDNA) to Characterize the Dynamic Evolution of Molecular Subtypes in Extensive-Stage Small Cell Lung Cancer During First-Line Chemoimmunotherapy	nan	NOT_YET_RECRUITING
The Association of G9a Protein and Clinical Outcome of Patients With Vulvar Cancer	nan	UNKNOWN
Exploiting Epigenome Editing in Kabuki Syndrome: a New Route Towards Gene Therapy for Rare Genetic Disorders	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a SETD2 binder may also engage these)

Protein	Name	Similarity
E9Q5F9	—	1.000	E9Q5F9 →
ASH1L	Histone-lysine N-methyltransferase ASH1L	1.000	landscape →
Q9UKL3	—	1.000	Q9UKL3 →
Q9WUF3	—	0.997	Q9WUF3 →
Q99MY8	—	0.996	Q99MY8 →
MAP3K19	Mitogen-activated protein kinase kinase kinase 19	0.996	landscape →
Q7Z570	—	0.995	Q7Z570 →
MKI67	Proliferation marker protein Ki-67	0.995	landscape →
Q28DZ0	—	0.995	Q28DZ0 →
A2AEY4	—	0.995	A2AEY4 →
Q92628	—	0.995	Q92628 →
O88466	—	0.994	O88466 →
Q5DTW7	—	0.994	Q5DTW7 →
Q0VAV2	—	0.994	Q0VAV2 →
F6ULY3	—	0.994	F6ULY3 →
CDCA2	Cell division cycle-associated protein 2	0.994	landscape →
TET1	Methylcytosine dioxygenase TET1	0.994	landscape →
A0A087WXM9	—	0.994	A0A087WXM9 →
Q86UW6	—	0.993	Q86UW6 →
E5FYH0	—	0.993	E5FYH0 →
Q4V7J0	—	0.993	Q4V7J0 →
Q99590	—	0.992	Q99590 →
E1BC15	—	0.992	E1BC15 →
Q86XD8	—	0.992	Q86XD8 →
B0QZF7	—	0.992	B0QZF7 →
A4IGL8	—	0.992	A4IGL8 →
O94687	—	0.992	O94687 →
A4D1E1	—	0.992	A4D1E1 →
Q6J6J0	—	0.992	Q6J6J0 →
E5FYH1	—	0.992	E5FYH1 →